The week of July 13–17, 2026, may well be remembered as the most consequential earnings week of the third quarter. Nearly every corner of the U.S. economy is represented: mega-cap banking, global semiconductor equipment, enterprise storage, streaming entertainment, managed healthcare, aerospace, pharma, and property insurance. Together, these 20 companies constitute trillions of dollars in combined market capitalization and serve as reliable economic barometers for investors trying to gauge the health of both Wall Street and Main Street.
The broader backdrop is one of cautious optimism. The S&P 500 has recovered meaningfully from earlier-year turbulence as geopolitical uncertainties and trade policy volatility gave way to a resilient U.S. corporate earnings season. The Finance sector, in particular, enters Q2 reporting with estimates suggesting robust year-over-year profit growth, fueled by elevated capital markets activity, strong fee income, and the late-cycle realization of higher net interest margins. Simultaneously, the technology segment — especially semiconductor-adjacent names — carries high expectations given AI-driven capex cycles that show little sign of slowing.
What follows is a detailed, company-by-company earnings preview organized by reporting day and sector.
Fastenal Company, the Winona, Minnesota-based industrial and construction supplies distributor, kicks off the earnings week before the market opens on Monday, July 13. Fastenal operates one of the most extensive B2B distribution networks in North America, supplying everything from fasteners to safety equipment via its proprietary Onsite and FMI (Fastenal Managed Inventory) programs embedded directly at customer facilities.
Current Financial Position: Fastenal demonstrated steady momentum in Q1 2026, posting revenue of $2.20B (up from $2.08B in Q2 2025) and EPS of $0.30, meeting consensus expectations. The company has consistently delivered on or above Wall Street's forecasts in recent quarters, with earnings surprises of +2.68%, -2.39%, +0.35%, and +0.44% over the trailing four quarters. Fastenal's business model, anchored in long-term customer relationships and embedded inventory systems, provides a degree of revenue predictability that many industrial distributors lack.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 EPS of $0.33 (up ~14% year-over-year from $0.29 in Q2 2025) on revenue of approximately $2.33–2.34B (up ~12% YoY from $2.08B). EBITDA is expected to reach roughly $535M, with net income in the range of $364–387M. Barclays analyst Guy Hardwick maintained an Equal-Weight rating on FAST with a raised price target of $47.
Why It Matters: Fastenal's results function as an early-cycle industrial demand gauge. A strong beat and raised outlook would signal healthy manufacturing activity and capital expenditure trends across the U.S. industrial base, positively impacting sentiment in peers like W.W. Grainger and MSC Industrial. Investors should watch daily sales growth (consensus estimate: $32.12/day vs. $29.90 a year ago), FMI program penetration, and any commentary on end-market demand across manufacturing, construction, and government channels.
Tuesday delivers what may be the single most important day of the earnings season: five of the largest U.S. banks reporting simultaneously. Their results will set the tone for rate sensitivity, credit quality, capital markets health, and consumer spending expectations across the entire financial sector.
The world's most profitable bank by net income, JPMorgan Chase & Co., reports before the market opens on Tuesday. Under CEO Jamie Dimon, JPMorgan has consistently set the standard for large-cap banking execution and is the first major bank to report each quarter — making its results and management commentary enormously influential for the sector.
Current Financial Position: JPMorgan delivered a powerful Q1 2026, with EPS of $5.94 crushing consensus of $5.47 by $0.47 (an 8.56% beat). The bank's diversified model — spanning Consumer & Community Banking, the Commercial & Investment Bank, Asset & Wealth Management, and Corporate — has benefited from elevated capital markets activity, strong loan growth, and a net interest income base that remains robust even as the Fed holds rates steady. The firm's Tier 1 capital ratios remain well above regulatory minimums, and it has maintained a Moderate Buy consensus rating with an average analyst price target around $338–$356.
Q2 2026 Consensus Estimates: Wall Street consensus points to EPS of approximately $5.44–$5.61 for Q2 2026, representing roughly 9–10% growth versus $4.96 in Q2 2025. Net revenue is projected at $48.6–50.4B, with investment banking fees expected up ~10–20% YoY and market revenues (trading) anticipated to rise ~11%. Net interest income is guided slightly below Q1's $23.2B, reflecting deposit repricing dynamics. Among 26 analysts, 10 hold Strong Buy, 2 Moderate Buy, and 14 Hold ratings.
Why It Matters: Jamie Dimon's economic outlook commentary is invariably market-moving. Markets will be sensitive to any shifts in tone regarding the U.S. consumer, credit quality, the trajectory of commercial real estate, and geopolitical risk. Given JPMorgan's track record of beating estimates in four of the last five quarters, the bar is high — but so is investor confidence.
View JPM AI Trading Bot here:
AVGO, WDC, JPM, JNJ, NEE - Cross-Asset Intelligence Bot with corridor TP 3% / SL 2%, 60min
Bank of America Corporation, headquartered in Charlotte, North Carolina, is one of the most rate-sensitive of the large banks, making it a pivotal read on the net interest income environment.
Current Financial Position: BAC entered Q2 2026 with strong momentum after Q1 delivered +9% NII growth, +290 basis points of operating leverage, and a 16% ROTCE. Q1 EPS came in at $1.11, topping the $1.01 estimate by ~10%. Consumer banking, wealth management, and global markets all showed positive trends, and the bank's massive deposit base gives it structural sensitivity to rate movements. BAC has outpaced estimates in three of the last four quarters, with an average surprise of ~5%.
Q2 2026 Consensus Estimates: Analysts project EPS of $1.11–$1.12 for Q2 2026, up from $0.89 in Q2 2025 — representing approximately a 26% YoY increase. Revenue consensus stands at approximately $30.3–30.7B. The Zacks Consensus Estimate for Q2 was revised upward to $1.13 per share in recent weeks.
Why It Matters: BAC is the purest large-bank proxy for U.S. consumer health and NII dynamics. Investors will monitor deposit beta trends, credit card delinquency rates, and any guidance updates on full-year NII. With the Fed holding rates and the yield curve still below historical norms, how BAC navigates the remainder of 2026 will be critical for the entire banking sector's valuation.
Goldman Sachs Group, Inc. is the world's preeminent investment bank and a dominant force in trading, M&A advisory, and asset management. Its Q2 report is a direct read on the health of global capital markets.
Current Financial Position: Goldman delivered an outstanding Q1 2026, with EPS of $17.55 — crushing consensus of $16.37 by 7.21%. Q1 revenue came in at approximately $15.06B, slightly above the $14.99B estimate. The firm's Global Banking & Markets segment drove performance through robust trading revenues and strong M&A advisory pipelines. Goldman's ROTCE for the quarter was solidly above its long-term targets, reflecting the leverage of its capital-light advisory and markets businesses in a volatile-but-active environment.
Q2 2026 Consensus Estimates: Wall Street projects Q2 2026 EPS of approximately $14.10–$14.47 — representing ~32–33% growth versus $10.91 in Q2 2025. Revenue is expected to reach approximately $15.8–$16.49B, up ~13% YoY, with Global Banking & Markets revenue alone estimated at ~$12.11B. The EPS sequential decline from Q1's $17.55 reflects the typically stronger Q1 for capital markets. The consensus analyst rating has been "Hold" on the stock, with Wells Fargo maintaining an Overweight rating and a price target of $785.
Why It Matters: Goldman Sachs is the "pure play" for capital markets sentiment. A strong beat would validate the M&A and IPO pipeline that has been building since mid-2025, and management's tone on deal activity, private equity sponsor activity, and Fixed Income/Equities trading performance will be closely scrutinized by both sector investors and macro strategists.
View GS AI Trading Bot here:
MS, GS, SCHW, IBKR, HOOD - AI Trading Agent (5 Tickers, Investment Banks, Brokers), 60min
Wells Fargo & Company, the San Francisco-based bank still operating under a Federal Reserve asset cap imposed following its 2016 fake accounts scandal, enters Q2 earnings with rising NII and a focus on efficiency transformation.
Current Financial Position: WFC had a mixed Q1 2026: earnings missed Zacks Consensus Estimates due to higher expenses and provisions, but NII improvement and stronger non-interest income offered partial offset. Q1 EPS of $1.60 beat the $1.58 estimate by 1.28%. The bank has been actively streamlining its organizational structure, closing branches, and reducing headcount — cost initiatives that are beginning to show in the expense base.
Q2 2026 Consensus Estimates: Analysts expect Q2 2026 EPS of $1.71–$1.74 (up approximately 12–13% YoY from $1.54 in Q2 2025) on revenues of approximately $21.83–21.85B (up ~4.7% YoY). NII is projected at $12.36B (a 5.6% YoY rise), with Investment Banking revenues expected up ~25.8% YoY. WFC carries a Zacks Rank of #3 (Hold) and a positive Earnings ESP of +0.09%, historically consistent with a beat.
Why It Matters: Wells Fargo remains a "show me" story. Investors want evidence that the efficiency transformation is accelerating and that the Fed asset cap — which has constrained growth for years — may eventually be lifted. Mortgage banking commentary will also matter given the mid-6% rate environment. Any signal of improving return on equity or an update on regulatory status could be a significant catalyst.
Citigroup Inc., under CEO Jane Fraser's sweeping restructuring initiative, is arguably the most operationally dynamic of the major U.S. banks right now. Its Q2 print arrives as it undergoes a multi-year simplification of its global footprint and business mix.
Current Financial Position: Q1 2026 was a landmark quarter for Citi, with EPS of $3.06 dramatically beating the $2.65 consensus by 15.4%, and revenue of $24.63B topping the $23.60B estimate by $1B. The outsized Q1 beat reflected strength across Institutional Clients Group (ICG), Services, and Markets, demonstrating that Fraser's restructuring is beginning to deliver tangible results. Citi has beaten estimates in four consecutive quarters.
Q2 2026 Consensus Estimates: Wall Street projects EPS of approximately $2.62–$2.73 for Q2 2026 (up ~33–35% YoY from $1.96) on revenues of approximately $23.47–23.66B (up ~8% YoY). For the full year, analysts project EPS of $10.72–$10.83, up approximately 35–36% from 2025. The sequential EPS decline from Q1's $3.06 reflects normalizing results as one-time benefits unwind.
Why It Matters: Citi is a "turnaround trade" in focus. Investors want confirmation that restructuring savings are sustainable, that credit quality in the institutional book is holding, and that the global services franchise — Treasury and Trade Solutions, Securities Services — continues to grow. Jane Fraser's commentary on the pace of the transformation and any updates on international divestitures will be pivotal.
ASML Holding N.V., the Dutch semiconductor equipment giant and sole manufacturer of Extreme Ultraviolet (EUV) lithography systems, is one of the most strategically important companies in the global technology ecosystem. Its Q2 2026 report represents one of the most anticipated semiconductor earnings events of the year.
Current Financial Position: ASML had a strong Q1 2026, reporting net sales of €8.8B and net income of €2.8B, which allowed management to raise its 2026 full-year revenue outlook to €36–40B (from a previous range) with gross margins expected at 51–53%. ASML guided Q2 2026 net sales specifically at €8.4–9.0B with a gross margin of 51–52%, noting that revenue remains weighted toward the second half of the year. The company beat Q1 EPS of $7.38 (consensus), with a full-year 2026 EPS consensus around $36.62.
Q2 2026 Consensus Estimates: Analyst consensus for Q2 2026 points to EPS of approximately $8.10–$8.67 and revenue of approximately $10.0–10.37B (USD). In EUR terms, this aligns with ASML's own guidance range. Bookings — a critical forward indicator — will be closely watched; in the comparable prior-year quarter, bookings of €5.54B exceeded expectations by ~25%, but the full-year 2025 narrative included cautionary commentary on 2026 growth.
Why It Matters: ASML is a monopoly in EUV lithography — no chip at 7nm or below can be made without its machines. Its earnings are a proxy for the entire semiconductor investment cycle. Investors will focus on: (1) net bookings, which signal demand from TSMC, Samsung, and Intel 6–18 months forward; (2) High NA EUV ramp commentary, as these next-generation systems represent the highest-margin future revenue stream; (3) any incremental commentary on export controls to China (ASML's single largest customer geography by revenue); and (4) FY2026 guidance reaffirmation given a backdrop of elevated geopolitical and tariff-related uncertainty.
View ASML AI Trading Bot here:
LRCX, TER, AMAT, KLAC, AMKR, ASML - AI Trading Agent (6 Tickers, Semiconductor Manufacturing), 60min
Johnson & Johnson, the New Brunswick, New Jersey-based healthcare conglomerate that completed the separation of its Consumer Health segment (Kenvue) in 2023, now operates as a pure-play pharmaceutical and MedTech company.
Current Financial Position: JNJ has delivered consistent beats in recent quarters. Q1 2026 EPS of $2.70 topped the $2.68 consensus by 0.85%, with revenue of $24.06B beating the $23.61B estimate by 1.89%. The company raised its full-year 2026 guidance, lifting the midpoint of projected sales to $100.8B and adjusted EPS to $11.55. JNJ has surpassed Wall Street's EPS estimates in the past four consecutive quarters.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 EPS of approximately $2.83–$2.86 (up ~2–3% YoY from $2.77) on revenues of approximately $25.0B (up ~9.4% YoY from $22.3B consensus in Q2 2025). For full year 2026, the consensus EPS stands at $11.57, up 7.2% from 2025.
Why It Matters: JNJ's report provides a window into pharmaceutical innovation (Darzalex, Tremfya, Rybrevant pipeline), MedTech procedure volume recovery (electrophysiology, orthopedics), and the ongoing integration of Shockwave Medical. Investors will also be focused on any talc litigation updates and oncology pipeline readouts. With the stock hovering near fair value relative to its long-term growth rate, a guidance raise or surprise on flagship drugs could provide meaningful upside.
View JNJ AI Trading Bot here:
AVGO, WDC, JPM, JNJ, NEE - Cross-Asset Intelligence Bot with corridor TP 3% / SL 2%, 60min
Morgan Stanley, headquartered in New York City, has transformed itself over the past decade from a predominantly trading-focused institution into a diversified financial services powerhouse — with Wealth Management now generating a substantial and recurring portion of total revenues.
Current Financial Position: Morgan Stanley has beaten EPS estimates in each of the last four quarters, including a 28.2% EPS surge anticipated YoY in Q2. Q1 2026 results have not been individually referenced yet this week, but the firm's consistent trajectory in wealth management (bolstered by the E*TRADE and Eaton Vance acquisitions) and its Institutional Securities division's capture of growing capital markets fees support confidence into Q2.
Q2 2026 Consensus Estimates: Consensus EPS for Q2 2026 is approximately $2.73–$2.92 (up ~28–37% YoY from $2.13 in Q2 2025) on revenue of approximately $19.28–$19.62B. For full year 2026, analysts forecast EPS of $11.90, up 16.6% from $10.21 in 2025.
Why It Matters: Morgan Stanley's wealth management segment — one of the largest in the world — provides a stable backdrop of fee-based revenues. Q2 results will shed light on client asset flows, advisory fee growth, the health of the IPO/underwriting pipeline, and any momentum in fixed-income and equity trading. The bank's ability to maintain high ROE while scaling Wealth Management will be the defining narrative of the year.
View MS AI Trading Bot here:
MS, GS, SCHW, IBKR, HOOD - AI Trading Agent (5 Tickers, Investment Banks, Brokers), 60min
BlackRock, Inc. is the world's largest asset manager with over $11 trillion in assets under management (AUM) and a business model that monetizes financial markets' breadth and scale.
Current Financial Position: BlackRock has been on an impressive growth trajectory. Q1 2026 is expected to have maintained the momentum established in prior quarters — with the firm's iShares ETF franchise, Aladdin platform, and alternative asset management all expanding. BLK beat estimates by 7.22% in Q2 2025 ($12.05 actual vs. $10.71 estimate), and by 10.24% in Q1 2025 ($11.30 actual vs. $10.25 estimate). For full year 2026, analysts forecast EPS of $53.64, up 11.54% YoY.
Q2 2026 Consensus Estimates: Wall Street projects Q2 2026 EPS of approximately $12.55–$12.57 (up ~4–7% YoY from $12.05 in Q2 2025) on revenues of approximately $6.68–$6.80B. EBITDA is estimated at approximately $2.5–$2.6B.
Why It Matters: BlackRock's AUM growth (and, by extension, fee revenues) is tightly linked to equity and fixed-income market performance. Q2 2026 saw healthy equity market appreciation globally, which should have driven AUM-related management fees higher. Investors will also watch for updates on BlackRock's private markets expansion — its GIP and Preqin acquisitions — as the firm pushes deeper into alternative investments, an area with materially higher margins than its public markets ETF business.
The Bank of New York Mellon Corporation, commonly known as BNY Mellon, is one of the world's leading custody banks and the largest securities servicer by assets under custody/administration globally, with approximately $52 trillion in AUC/A.
Current Financial Position: BNY Mellon's business model is heavily fee-based, with custody fees, clearing fees, and investment management revenues comprising the majority of revenues. The bank has historically benefited from higher interest rates as its massive book of non-interest-bearing deposits generates NII that flows almost entirely to the bottom line. Q1 2026 EPS came in at $2.25, with revenue of approximately $5.41B.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 EPS of approximately $2.20 (a modest sequential decline from Q1) on revenues of approximately $5.34–5.42B.
Why It Matters: BNY Mellon's results reflect the health of global capital markets from a "plumbing" perspective — the volume of securities transactions, the velocity of money flows, and the demand for custody and clearing services. Investors will monitor AUC/A trends, net interest income sensitivity to the Fed's rate posture, and any updates on the firm's Pershing platform, which serves a large swath of registered investment advisors and broker-dealers.
PNC Financial Services Group, Inc. is a Pittsburgh, Pennsylvania-based diversified financial services company with a strong regional banking franchise spanning the eastern and southern United States, augmented by the 2021 BBVA USA acquisition.
Current Financial Position: PNC delivered a strong Q1 2026, with EPS of $4.32 beating the $3.92 consensus by $0.40. The bank has beaten estimates in each of the last four quarters, with a recent trend of upward estimate revisions. PNC's management has emphasized a disciplined NII growth path, technology investment, and capital returns as core priorities.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 EPS of approximately $4.41–$4.55 (up ~18% YoY from $3.85) on revenues of approximately $6.39–$6.50B. For full year 2026, analysts forecast EPS of $18.81, up ~13.4% YoY. UBS maintains a Buy rating on PNC stock.
Why It Matters: PNC sits at the intersection of commercial and consumer banking, offering a clear window into mid-market lending activity, commercial real estate, and Main Street credit trends. In 2026, its potential acquisition of Fiserv's STAR Network has emerged as a strategic news item; any commentary on this or on organic growth initiatives will be watched closely by investors.
View PNC AI Trading Bot here:
Gold & Silver Mining, Energy, Finance, Quantum Computing & AI Infrastructure - AI Trading Agent (25 Tickers), 15min
Elevance Health, Inc. (formerly Anthem), the Indianapolis-based health insurance giant operating Blue Cross Blue Shield plans across dozens of states, faces one of the most consequential earnings reports in the managed care sector this quarter.
Current Financial Position: Elevance has been in the eye of a perfect storm: rising Medical Loss Ratios (MLRs), Medicare Advantage margin pressure, and a Medicaid redetermination headwind — all weighing on profitability in 2025 and into 2026. Q2 2025 EPS of $8.84 missed Wall Street's $9.16 estimate. The full-year 2026 EPS forecast of $26.92 represents an ~11% decline from $30.29 in 2025. Elevance also recently filed a lawsuit against CMS over Medicare star ratings and lost bonus payments.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 EPS of approximately $6.15–$6.18 (down ~30% YoY from $8.84) on revenues of approximately $48.82B. For full year 2026, consensus EPS stands at $26.92, with management guiding to $26.75 per share. Wall Street Zen recently upgraded ELV to "Buy."
Why It Matters: Elevance is the defining test case for whether managed care companies have successfully managed the medical cost inflation wave that began in late 2024. The market will be looking for stabilization (or better, improvement) in the Medical Loss Ratio, early evidence that pricing actions are flowing through in commercial and government books, and any guidance revision. A positive surprise could lift the entire managed care sector, given how deeply the group has underperformed.
Taiwan Semiconductor Manufacturing Company Ltd. (TSMC), headquartered in Hsinchu, Taiwan, is the world's largest and most technologically advanced contract chipmaker, manufacturing chips for virtually every leading technology company on the planet — from Apple and NVIDIA to AMD, Broadcom, and Qualcomm.
Current Financial Position: TSMC delivered one of the strongest Q1 2026 prints in its history. Q1 revenue hit US$35.90B (NT$1,134.10B), up 40.6% YoY in USD terms and above consensus. Net income surged 58.3% YoY to NT$572.48B, with EPS of US$3.49 per ADR — beating the $3.26 consensus by $0.23. Gross margin hit 66.2%, with advanced nodes (3nm = 25% of wafer revenue, 5nm = 36%) driving a superior product mix. Management guided Q2 revenue at $39.0–$40.2B (a sequential midpoint rise of ~13%) with gross margin of 65.5%–67.5% and operating margin of 56.5%–58.5%.
Q2 2026 Consensus Estimates: Analyst consensus for Q2 2026 EPS stands at approximately $3.69–$3.80 per ADR (up ~8–9% from Q1's $3.49). Revenue consensus is approximately $39.76B, consistent with management's own guidance midpoint. Full-year 2026 revenue growth is guided above 30% in USD terms, supported by insatiable demand for AI accelerators and high-performance computing chips.
Why It Matters: TSMC's report is the single most important data point for the global AI chip investment thesis. Management's commentary on demand visibility from hyperscalers (Meta, Microsoft, Google, Amazon), Apple's iPhone cycle, and any updates on the 2nm/A16 technology node ramp will set expectations for the entire semiconductor ecosystem. TSMC's capex plans — guided toward the high end of $52–56B for 2026 — also carry implications for equipment makers like ASML, KLA, and Lam Research. Geopolitical commentary regarding the U.S.-Taiwan relationship and export control dynamics will be closely monitored.
View TSM AI Trading Bot here:
NVDA, AVGO, AMD, TSM, MU - AI Trading Agent (5 Tickers, Semiconductors), 60min
UnitedHealth Group Incorporated, the Minnetonka, Minnesota-based health care giant encompassing the UnitedHealthcare insurance arm and Optum health services division, enters Q2 earnings under an elevated level of investor scrutiny.
Current Financial Position: The road to Q2 has not been without turbulence. Following CEO Andrew Witty's unexpected resignation in 2025, a DOJ investigation into Medicare billing practices, and a suspension of annual guidance, the company has undertaken a significant internal review. The Q1 2026 results signaled a meaningful recovery — adjusted EPS of $7.23 topped Wall Street's forecasts, and management raised its full-year 2026 adjusted EPS guidance to >$18.25 (up from >$17.75). Revenue guidance was maintained at >$439B.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 EPS of approximately $4.84–$4.85 (up ~18.6% from $4.08 in Q2 2025) on revenues that align with management's full-year trajectory. For full year 2026, consensus EPS stands at approximately $18.32, up 12.1% YoY.
Why It Matters: UnitedHealth's Q2 is not just about the numbers — it is about narrative restoration. Markets will want to see stabilizing Medical Loss Ratios in UnitedHealthcare, continued execution at Optum (both Optum Health and OptumRx), and ideally some resolution of clarity around the DOJ investigation. The company's independent review program findings (shared in early 2026) will also be a reference point. Any further guidance raise, combined with reassuring legal commentary, could be a significant positive re-rating catalyst for UNH and the broader managed care sector.
GE Aerospace, the pure-play aerospace and defense engine manufacturer spun off following the breakup of the old General Electric conglomerate, has rapidly emerged as one of the strongest secular growth stories in the industrials sector.
Current Financial Position: GE Aerospace is executing from a position of exceptional strength. Q1 2026 revenue of $10.72B and EPS of $1.72 were strong, with management citing full-year EPS guidance of $7.10–$7.40 and free cash flow guidance of $8.0–$8.4B, both trending toward the high end. Services revenue is expected to grow by ~$4B YoY for the full year, and 95% of Q2 spare parts revenue is already in the backlog. The company's LEAP and GE9X engine programs — and the attendant maintenance, repair, and overhaul (MRO) services stream — are generating powerful incremental cash flows as global air travel demand continues to exceed pre-pandemic levels.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 revenue of approximately $11.77B (up ~23% YoY and ~10% sequentially) with EPS of approximately $2.04 (up ~33% YoY) and free cash flow per share near $2.43. Full-year 2026 operating profit guidance stands at $9.85–$10.25B.
Why It Matters: GE Aerospace's Q2 print will be scrutinized for evidence that its services revenue supercycle — driven by aging global fleets and unprecedented shop visit demand — is sustainable. Investors will also watch commentary on the 9X engine program profitability, Middle East conflict impact assumptions, and any Defense & Propulsion Technologies (DPT) segment updates. With all Q2 shop visits already "off wing" and well-oversubscribed, the setup for a Q2 beat appears constructive.
View GE AI Trading Bot here:
Industrials (BA, CAT, DE, ETN, GE, HON, LMT, MMM, RTX, UPS) - AI Trading Agent with corridor TP 3% / SL 2% (10 Tickers), 60min
Netflix, Inc., the Los Gatos, California-based streaming video pioneer, enters Q2 earnings with a complex but watchable setup: strong fundamental tailwinds from advertising and pricing, offset by peak content amortization costs and lingering post-guidance-miss overhang from Q1.
Current Financial Position: Q1 2026 produced a narrow beat on revenue but guided Q2 below expectations, triggering a ~10% stock decline. Netflix raised its U.S. subscription prices across all tiers in late March 2026, with the bulk of incremental revenue expected to flow through in Q2. The advertising tier surpassed 250 million global monthly active viewers by Q2, up from 190 million months earlier, with over half of new sign-ups choosing an ad-supported plan. Netflix maintained full-year revenue guidance of $50.7–$51.7B and raised its free cash flow guidance to approximately $12.5B (from $11.0B).
Q2 2026 Consensus Estimates: Netflix itself guided Q2 revenue of $12.57B (consensus: $12.57–$12.84B, up ~13.5% YoY) with an operating margin of 32.6% (down from 34.1% in Q2 2025, due to peak content amortization). Consensus EPS is approximately $0.79–$0.80 per share.
Why It Matters: Netflix's quarter will test whether the ad-tier monetization narrative is delivering real numbers. At its May 2026 Upfront presentation, the company disclosed targets of ~$3B in 2026 ad revenues and announced an Audience Insights API and expanded programmatic buying access. Investors will look for: (1) subscriber additions and any guidance on the trajectory to 325M+ members; (2) evidence that Q2 represents the advertising inflection point; (3) commentary on the FIFA World Cup content engagement and live programming strategy; and (4) the pace of content amortization normalization in H2 2026. Netflix's premium valuation relative to streaming peers makes execution against management's own guidance non-negotiable.
Important Note: Seagate Technology operates on a non-standard fiscal year ending in June. The report due on July 16, 2026, covers Seagate's fiscal fourth quarter of 2026 (the quarter ended June/July 2026), not Q2 calendar 2026 (which Seagate reported in January 2026). This is a full fiscal year-end report.
Seagate Technology Holdings plc, headquartered in Dublin (Ireland) with operations centered in California, is the world's largest hard disk drive (HDD) manufacturer, and a critical infrastructure provider for global data centers.
Current Financial Position: Seagate is in the midst of a historic HDD supercycle driven by AI infrastructure build-out. Fiscal Q3 2026 (ended March 2026) was a blowout: revenue of $3.11B (+44% YoY) beat estimates of $2.95B, and EPS of $4.10 demolished the $3.48 consensus by 17.82%. The stock surged 18% after hours following that print. Management then issued fiscal Q4 guidance of **$3.45B revenue** (vs. $3.15B consensus estimate) and ~$5.00 EPS (vs. $3.97 consensus) — representing a staggering ~26% above-consensus EPS guide. Data center revenue in Q3 grew 55% YoY, with 175 exabytes shipped. Non-GAAP gross margin hit record levels.
Fiscal Q4 2026 Consensus Estimates: Given the company's own guidance of $5.00 EPS (+/- $0.20) and revenue of approximately $3.45B (+/- $100M), consensus estimates have converged around these figures. Annual EPS for fiscal 2026 is estimated at approximately $14.93.
Why It Matters: Seagate is arguably the most visible direct beneficiary of AI's insatiable demand for storage. Hyperscalers need nearline HDD capacity to store the exponentially growing datasets generated by AI workloads, and Seagate's areal-density-driven, high-capacity drives are ideally positioned to serve that demand. The fiscal Q4 report and management guidance for fiscal 2027 will be critical reads on the durability of the AI storage supercycle. Any incremental commentary on pricing power, capacity additions, and demand visibility from cloud customers will set the tone for the entire data storage sector.
View STX AI Trading Bot here:
AAPL, AMD, NVDA, EBAY, STX - AI Trading Agent (5 Tickers), 15min
Abbott Laboratories, headquartered in Abbott Park, Illinois, is a diversified healthcare company with leading positions in medical devices, diagnostics, established pharmaceuticals, and nutrition products.
Current Financial Position: Q1 2026 delivered in-line results: EPS of $1.15 met consensus, while revenue of $11.16B beat the $10.99B estimate by 1.5%. However, the stock fell ~5% after Abbott cut its full-year 2026 EPS guidance to $5.38–$5.58 (from $5.55–$5.80), reflecting approximately $0.20 EPS dilution from its $23 billion acquisition of Exact Sciences — a move that dramatically expands its oncology diagnostics capabilities. Management projects full-year comparable sales growth of 6.5%–7.5%.
Q2 2026 Consensus Estimates: Abbott issued Q2 2026 EPS guidance of $1.25–$1.31, below the prior consensus of $1.32–$1.37. Analyst consensus has settled around $1.28 (up ~1.6% from $1.26 in Q2 2025) on revenues of approximately $12.5B (range: $12.2–$12.7B). The company has beaten or met EPS estimates in each of the last four quarters.
Why It Matters: Abbott's Q2 print offers a window into high-growth medical device segments — particularly electrophysiology (up 13% in Q1), rhythm management, heart failure, and continuous glucose monitoring (FreeStyle Libre). The integration progress of Exact Sciences and any update on the oncology diagnostics revenue ramp will be closely watched. Nutrition segment recovery in developing markets and any diagnostics volume commentary (including COVID-19 testing trends) will round out the key investor focus areas.
The Travelers Companies, Inc., headquartered in New York City, is one of the largest property & casualty insurance companies in the United States and a component of the Dow Jones Industrial Average.
Current Financial Position: Travelers delivered an exceptional Q1 2026, with EPS of $7.71 dramatically beating the $6.80 consensus by $0.91 (or 10.94%), driven by favorable catastrophe loss experience and strong underlying underwriting margins. Q1 net income came in at $1.71B against revenue of $11.92B. The company has beaten EPS estimates in each of its last four consecutive quarters. Travelers is the dominant writer of commercial lines in the U.S. and has consistently demonstrated above-industry pricing discipline.
Q2 2026 Consensus Estimates: Analysts project Q2 2026 EPS of approximately $4.87–$5.27 (down ~25% YoY from $6.51 in Q2 2025) on revenues of approximately $11.0–$11.23B. For full year 2026, analysts expect EPS of $28, up 1.5% from $27.59 in 2025. The consensus analyst view is "Hold", with 8 Strong Buy, 1 Moderate Buy, 16 Hold, and 2 Sell-equivalent ratings among 27 covering analysts; the Street-high price target of $350 implies ~10% upside from current levels.
Why It Matters: The Q2 property insurance calendar can be heavily influenced by catastrophe activity — spring storm seasons, tornado outbreaks, and hail events — and Q2 2026's catastrophe losses relative to Q2 2025's favorable baseline explain the projected EPS decline. Investors will want to understand the underlying "core" underwriting performance, which strips out cats, to assess whether premium rate increases are holding or accelerating in Personal Lines (homeowners, auto) and in Business Insurance (commercial lines). Net investment income trends — which have benefited from higher reinvestment yields — will also be a key swing factor. Any guidance commentary on full-year combined ratio targets could move the stock.
| Sector | Key Companies | Primary Focus |
|---|---|---|
| Industrials/Distribution | Industrial demand, daily sales trends | |
| Mega-Cap Banking | NII, credit quality, capital markets | |
| Semiconductor Equipment | EUV bookings, export controls, 2026 guidance | |
| Pharmaceuticals & MedTech | Drug pipeline, device procedure volumes | |
| Financial Services/Asset Mgmt | AUM growth, fee revenues, NII | |
| Managed Healthcare | MLR stabilization, Medicare Advantage | |
| Semiconductors/Contract Mfg | AI chip demand, advanced node ramp | |
| Aerospace & Defense | Engine services, backlog, FCF | |
| Streaming Entertainment | Ad revenue, subscriber growth, margin | |
| Data Storage | AI HDD demand, fiscal Q4 2026 | |
| P&C Insurance | Catastrophe losses, combined ratio |
Earnings season has arrived at a moment when investor confidence is broadly positive but selectively cautious. The S&P 500 Finance sector is expected to deliver one of its strongest year-over-year earnings growth quarters in recent memory, driven by capital markets resurgence and elevated trading volumes. The Federal Reserve has maintained its target range for the federal funds rate at 3.50–3.75% through Q2 2026, a stable rate environment that has helped NII hold up for banks even as deposit repricing dynamics create some sequential drag.
In technology, AI infrastructure spending has shown no signs of slowdown — a tailwind directly visible in TSMC's guidance, Seagate's unprecedented fiscal Q4 outlook, and ASML's upgraded full-year revenue range. The managed care sector, by contrast, is navigating the most difficult medical cost environment in a decade, making both UnitedHealth's and Elevance's reports potential inflection points for the group's prolonged underperformance.
For investors, the week of July 13–17 is not just about individual company beats or misses — it is about calibrating expectations for the remainder of 2026, understanding whether the U.S. economy is trending toward a soft landing or accumulating credit stress, and gauging whether the AI investment supercycle will extend into 2027 with the same intensity it has displayed over the past six quarters.
This article is provided for informational and educational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. All estimates and forecasts are based on analyst consensus data as of July 10, 2026, and are subject to change. Investors should conduct their own due diligence before making any investment decisions.
Tickeron AI Perspective